Cargando…

Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis

Dry eye disease (DED) is a multifactorial disease that causes ocular discomfort and visual impairment on a damaged ocular surface. Lifitegrast, a novel T-cell integrin antagonist, was approved in the United States in July 2016 as a 5% (50 mg/mL) ophthalmic solution for DED management. Currently, no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jing-Xing, Tsai, Yi-Yu, Lai, Chun-Ting, Li, You-Ling, Wu, Ying-Hsuen, Chiang, Chun-Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456613/ https://www.ncbi.nlm.nih.gov/pubmed/36078948 http://dx.doi.org/10.3390/jcm11175014

Ejemplares similares

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White, Darrell E, et al.
Publicado: (2019)

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
por: Godin, Morgan R, et al.
Publicado: (2017)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

Dry eye syndrome: developments and lifitegrast in perspective
por: Lollett, Ivonne V, et al.
Publicado: (2018)

Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease
por: Nichols, Kelly K, et al.
Publicado: (2018)

Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort
por: Gonzalez, Agustin L
Publicado: (2018)

Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study
por: Donnenfeld, Eric D., et al.
Publicado: (2016)

Lifitegrast: A novel drug for treatment of dry eye disease
por: Abidi, Afroz, et al.
Publicado: (2016)

Lifitegrast: a novel drug for patients with dry eye disease
por: Haber, Stacy L., et al.
Publicado: (2019)

Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials
por: Holland, Edward J., et al.
Publicado: (2021)

Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease
por: White, Darrell E, et al.
Publicado: (2023)

Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease
por: Semba, Charles P, et al.
Publicado: (2016)

Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra(®)) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease
por: Hovanesian, John A, et al.
Publicado: (2021)

The Effect of Lifitegrast on Refractive Accuracy and Symptoms in Dry Eye Patients Undergoing Cataract Surgery
por: Hovanesian, John, et al.
Publicado: (2020)

Longitudinal changes in dry eye symptoms and signs following lifitegrast therapy and relationship to tear osmolarity
por: Pepose, Jay S, et al.
Publicado: (2019)

Modulation of HLA-DR in dry eye patients following 30 days of treatment with a lubricant eyedrop solution
por: Fernandez, Karen B, et al.
Publicado: (2015)

LIFITEGRAST 5% FOR DRY EYE DISEASE: COMBINED EFFICACY AND SAFETY FROM FIVE RANDOMIZED CONTROLLED TRIALS
por: Gonzalez, Agustin L, et al.
Publicado: (2019)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
por: Nichols, Kelly K, et al.
Publicado: (2018)

Six months' treatment with lifitegrast in patients with moderate-to-severe symptomatic dry eye: a retrospective chart review
por: Atallah, Richard Teofilo, et al.
Publicado: (2019)

Allogeneic Umbilical Cord Plasma Eyedrops for the Treatment of Recalcitrant Dry Eye Disease Patients
por: Wong, Joy, et al.
Publicado: (2023)

Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptor
por: St. Peter, Deidre M, et al.
Publicado: (2023)

Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes
por: Shrivastava, Saurabh, et al.
Publicado: (2018)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Publicado: (2018)

Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment
por: Shen, Jingjing, et al.
Publicado: (2023)

Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes
por: Koh, Shizuka
Publicado: (2015)

A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
por: McMullin, David, et al.
Publicado: (2021)

Effect of Refresh Plus(®) preservative-free lubricant eyedrops on tear ferning patterns in dry eye and normal eye subjects
por: Alanazi, Saud A, et al.
Publicado: (2019)

Trehalose/hyaluronate eyedrop effects on ocular surface inflammatory markers and mucin expression in dry eye patients
por: Fariselli, Chiara, et al.
Publicado: (2018)

Prevention of Surgery-Induced Dry Eye by Diquafosol Eyedrops after Femtosecond Laser-Assisted Cataract Surgery
por: Yamazaki, Kenichiro, et al.
Publicado: (2022)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira, Rodrigo Carlos, et al.
Publicado: (2019)

Reduction of Artificial Tears and Use of Adjunctive Dry Eye Therapies After Lifitegrast Treatment: Evidence from Clinical and Real-World Studies
por: Nichols, Kelly K, et al.
Publicado: (2022)

Clinical Efficacy, Tolerability and Safety of a New Multiple-Action Eyedrop in Subjects with Moderate to Severe Dry Eye
por: Roszkowska, Anna Maria, et al.
Publicado: (2022)

Success of patient training in improving proficiency of eyedrop administration among various ophthalmic patient populations
por: Feng, Alexander, et al.
Publicado: (2016)

A randomized multicenter study comparing seawater washes and carmellose artificial tears eyedrops in the treatment of dry eye syndrome
por: Diaz-Llopis, Manuel, et al.
Publicado: (2019)

Clinical Efficacy of an Eyedrop Containing Hyaluronic Acid and Ginkgo Biloba in the Management of Dry Eye Disease Induced by Cataract Surgery
por: Fogagnolo, Paolo, et al.
Publicado: (2022)

Topical Omega-3 Fatty Acids Eyedrops in the Treatment of Dry Eye and Ocular Surface Disease: A Systematic Review
por: Paik, Benjamin, et al.
Publicado: (2022)

Success of patient training in improving proficiency of eyedrop administration among various ophthalmic patient populations [Corrigendum]
Publicado: (2017)

Short-term application of diquafosol ophthalmic solution benefits children with dry eye wearing orthokeratology lens
por: Yang, Yuanfang, et al.
Publicado: (2023)

Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model
por: Bang, Seung Pil, et al.
Publicado: (2019)

A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome
por: Pinto-Bonilla, Juan Carlos, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cbred2p34jkhbvsk65metlb12i